- Home
- PCVX vs TLX Comparison
PCVX vs TLX Comparison
Compare PCVX & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCVX
- TLX
- Stock Information
- Founded
- PCVX 2013
- TLX 2015
- Country
- PCVX United States
- TLX Australia
- Employees
- PCVX N/A
- TLX N/A
- Industry
- PCVX Biotechnology: Pharmaceutical Preparations
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- PCVX Health Care
- TLX Health Care
- Exchange
- PCVX Nasdaq
- TLX Nasdaq
- Market Cap
- PCVX 4.0B
- TLX 3.6B
- IPO Year
- PCVX 2020
- TLX N/A
- Fundamental
- Price
- PCVX $40.80
- TLX $10.25
- Analyst Decision
- PCVX Strong Buy
- TLX Strong Buy
- Analyst Count
- PCVX 8
- TLX 4
- Target Price
- PCVX $114.17
- TLX $21.00
- AVG Volume (30 Days)
- PCVX 1.5M
- TLX 101.9K
- Earning Date
- PCVX 11-05-2025
- TLX 01-01-0001
- Dividend Yield
- PCVX N/A
- TLX N/A
- EPS Growth
- PCVX N/A
- TLX N/A
- EPS
- PCVX N/A
- TLX 0.04
- Revenue
- PCVX N/A
- TLX $664,225,558.00
- Revenue This Year
- PCVX N/A
- TLX N/A
- Revenue Next Year
- PCVX N/A
- TLX N/A
- P/E Ratio
- PCVX N/A
- TLX $319.51
- Revenue Growth
- PCVX N/A
- TLX 55.35
- 52 Week Low
- PCVX $27.66
- TLX $8.93
- 52 Week High
- PCVX $116.00
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- PCVX 47.89
- TLX 44.85
- Support Level
- PCVX $43.12
- TLX $10.54
- Resistance Level
- PCVX $45.90
- TLX $11.00
- Average True Range (ATR)
- PCVX 1.86
- TLX 0.21
- MACD
- PCVX -0.59
- TLX -0.06
- Stochastic Oscillator
- PCVX 15.01
- TLX 4.43
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.